PT1646613E - Derivados de quinolina e quinazolina tendo afinidade para os receptores do tipo 5ht1 - Google Patents
Derivados de quinolina e quinazolina tendo afinidade para os receptores do tipo 5ht1 Download PDFInfo
- Publication number
- PT1646613E PT1646613E PT04763307T PT04763307T PT1646613E PT 1646613 E PT1646613 E PT 1646613E PT 04763307 T PT04763307 T PT 04763307T PT 04763307 T PT04763307 T PT 04763307T PT 1646613 E PT1646613 E PT 1646613E
- Authority
- PT
- Portugal
- Prior art keywords
- quinoline
- affinity
- quinazoline derivatives
- type receptors
- receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316915.8A GB0316915D0 (en) | 2003-07-18 | 2003-07-18 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1646613E true PT1646613E (pt) | 2008-06-19 |
Family
ID=27764115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04763307T PT1646613E (pt) | 2003-07-18 | 2004-07-15 | Derivados de quinolina e quinazolina tendo afinidade para os receptores do tipo 5ht1 |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US7279481B2 (pt) |
| EP (3) | EP1646613B1 (pt) |
| JP (1) | JP2006528146A (pt) |
| KR (1) | KR20060041242A (pt) |
| CN (1) | CN100441571C (pt) |
| AR (1) | AR046394A1 (pt) |
| AT (2) | ATE448205T1 (pt) |
| AU (1) | AU2004263268B2 (pt) |
| BR (1) | BRPI0412695A (pt) |
| CA (1) | CA2532452A1 (pt) |
| CY (1) | CY1107974T1 (pt) |
| DE (2) | DE602004012564T2 (pt) |
| DK (1) | DK1646613T3 (pt) |
| ES (2) | ES2302543T3 (pt) |
| GB (1) | GB0316915D0 (pt) |
| HK (1) | HK1089438A1 (pt) |
| HR (1) | HRP20080226T3 (pt) |
| IL (1) | IL173036A0 (pt) |
| IS (1) | IS2744B (pt) |
| MA (1) | MA27926A1 (pt) |
| MX (1) | MXPA06000716A (pt) |
| NO (1) | NO20060774L (pt) |
| NZ (1) | NZ544586A (pt) |
| PL (1) | PL1646613T3 (pt) |
| PT (1) | PT1646613E (pt) |
| RU (1) | RU2402533C2 (pt) |
| SI (1) | SI1646613T1 (pt) |
| TW (1) | TW200521115A (pt) |
| WO (1) | WO2005014552A1 (pt) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316915D0 (en) * | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| US8110595B2 (en) * | 2004-06-17 | 2012-02-07 | Cytokinetics, Inc. | Ureas and their use in the treatment of heart failure |
| KR100817538B1 (ko) * | 2006-07-05 | 2008-03-27 | 한국화학연구원 | 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물 |
| CA2673481A1 (en) * | 2006-12-19 | 2008-06-26 | University Of Virginia Patent Foundation | Combined effects of topiramate and ondansetron on alcohol consumption |
| US20100076006A1 (en) * | 2007-01-31 | 2010-03-25 | University Of Virginia Patent Foundation | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders |
| ATE499099T1 (de) | 2007-07-19 | 2011-03-15 | Esteve Labor Dr | Substituierte tetrahydro- chinolinsulfonamidverbindungen, ihre herstellung und ihre verwendung als medikamente |
| US20110065628A1 (en) * | 2007-08-27 | 2011-03-17 | University Of Virginia Patent Foundation | Medication Combinations for the Treatment of Alcoholism and Drug Addiction |
| WO2009108837A2 (en) * | 2008-02-28 | 2009-09-03 | University Of Virginia Patent Foundation | Serotonin transporter gene and treatment of alcoholism |
| WO2009132202A2 (en) | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| ES2358718T3 (es) * | 2008-05-06 | 2011-05-13 | Biedermann Motech Gmbh | Implante en forma de varilla, en concreto para la estabilización dinámica de la columna vertebral. |
| US20100298397A1 (en) * | 2009-05-19 | 2010-11-25 | Singh Nikhilesh N | Method of treatment of obsessive compulsive disorder with ondansetron |
| CN101671336B (zh) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
| EP2308850A1 (en) * | 2009-10-06 | 2011-04-13 | Laboratorios Del. Dr. Esteve, S.A. | Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments |
| EP2801625B1 (en) | 2010-07-02 | 2017-11-01 | University Of Virginia Patent Foundation | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| BR112014002939A2 (pt) * | 2011-08-09 | 2017-03-01 | Takeda Pharmaceuticals Co | composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1 |
| EA027743B1 (ru) | 2011-09-09 | 2017-08-31 | Юниверсити Оф Вирджиния Пэтент Фаундейшн | Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| AU2013259551B2 (en) * | 2012-05-09 | 2017-11-02 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| CN103508927A (zh) * | 2012-06-25 | 2014-01-15 | 天津药物研究院 | 一种2-甲磺酰氨基二苯醚的制备方法 |
| EP2907802B1 (en) | 2012-10-12 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| EP3072884B1 (en) | 2013-11-20 | 2020-01-01 | Sanwa Kagaku Kenkyusho Co., Ltd. | 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes |
| TN2016000418A1 (en) | 2014-04-11 | 2018-04-04 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof. |
| WO2016075314A1 (fr) | 2014-11-13 | 2016-05-19 | Institut National De La Recherche Agronomique | Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines |
| FR3028527A1 (fr) | 2014-11-13 | 2016-05-20 | Pivert | Identification de facteurs de transcription de yarrowia lipolytica |
| EP3395351A1 (en) | 2014-12-23 | 2018-10-31 | 4D Pharma Research Limited | Immune modulation |
| JP6427278B2 (ja) | 2014-12-23 | 2018-11-21 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | ｐｉｒｉｎポリペプチド及び免疫モジュレーション |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PT3650033T (pt) | 2015-06-15 | 2022-05-25 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| BR112017025005A2 (pt) | 2015-06-15 | 2018-08-07 | 4D Pharma Research Limited | composições compreendendo cepas baterianas |
| CN107847529B (zh) | 2015-06-15 | 2022-05-03 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41013A (fr) | 2015-11-20 | 2017-08-30 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| EA035949B1 (ru) | 2016-03-04 | 2020-09-04 | 4Д ФАРМА ПиЭлСи | Применение композиции, содержащей бактериальный штамм вида blautia hydrogenotrophica, и способ лечения или предотвращения висцеральной гиперчувствительности |
| TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| MA48939B1 (fr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| LT3638271T (lt) | 2017-06-14 | 2021-01-11 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterines padermes |
| MD3600364T2 (ro) | 2017-06-14 | 2020-12-31 | 4D Pharma Res Ltd | Compoziții care conţin tulpină bacteriană din genul Megasphaera și utilizări ale acestora |
| HUE053488T2 (hu) | 2017-06-14 | 2021-06-28 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
| CN108047143A (zh) * | 2017-12-18 | 2018-05-18 | 刘凤娟 | 一种用于治疗功能性胃肠病的5-羟色胺受体拮抗剂的合成方法 |
| FI3814347T3 (fi) | 2018-06-27 | 2023-06-12 | Bristol Myers Squibb Co | Naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina |
| KR20210024586A (ko) | 2018-06-27 | 2021-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2641602A (en) | 1950-11-29 | 1953-06-09 | Eastman Kodak Co | 1, 8-dihydroxy-5-nitro-4-hydroxyethylphenyl aminoanthraquinone compounds |
| US3937708A (en) * | 1971-06-07 | 1976-02-10 | Boehringer Ingelheim Gmbh | N-phenyl-imidazolidine-1-ones |
| US3975525A (en) * | 1971-06-07 | 1976-08-17 | Boehringer Ingelheim Gmbh | N-[4'-Imidazolidinon-(2)-yl-phenethyl]-N'-pyridyl-piperazines and salts thereof |
| US3992537A (en) * | 1971-06-07 | 1976-11-16 | Boehringer Ingelheim Gmbh | Pharmaceutical compositions containing an N-phenyl-imidazolidine-2-one and method of use |
| JPS5883677A (ja) | 1981-11-11 | 1983-05-19 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
| US4891275A (en) * | 1982-10-29 | 1990-01-02 | Norsk Hydro A.S. | Aluminum shapes coated with brazing material and process of coating |
| JPS6354363A (ja) | 1986-08-26 | 1988-03-08 | Ss Pharmaceut Co Ltd | キノリン誘導体 |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US4891375A (en) * | 1988-01-13 | 1990-01-02 | Pfizer Inc. | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds |
| JP2777159B2 (ja) | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | 環状アミン誘導体を含有する医薬 |
| GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| GB9300195D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| GB9308725D0 (en) * | 1993-04-27 | 1993-06-09 | Wyeth John & Brother Ltd | Piperazine derivatives |
| BRPI9708389B8 (pt) * | 1996-03-29 | 2015-12-08 | Duphar Int Res | compostos de piperazina e piperidina, composições farmacêuticas. |
| US5965560A (en) * | 1996-04-30 | 1999-10-12 | Warner-Lambert Company | Substituted piperazines and piperidines as central nervous system agents |
| GB2312843A (en) | 1996-05-07 | 1997-11-12 | Merck & Co Inc | Method of treating rheumatoid arthritis |
| AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| EP0900792B1 (en) * | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
| DE69819266T2 (de) * | 1997-09-02 | 2004-07-29 | Duphar International Research B.V. | Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten |
| SK285198B6 (sk) | 1997-10-27 | 2006-08-03 | Neurosearch A/S | Homopiperazínový derivát, farmaceutická kompozícia obsahujúca tento derivát a jeho použitie |
| CA2313125A1 (en) * | 1997-12-12 | 1999-06-24 | Laramie Mary Gaster | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
| UA62015C2 (en) * | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
| CN1158258C (zh) | 1999-06-24 | 2004-07-21 | 东丽株式会社 | 肾上腺素能α1B受体拮抗药 |
| ES2234683T3 (es) * | 1999-11-05 | 2005-07-01 | Smithkline Beecham Plc | Derivados de isoquinolina y quinazolina con actividad combinada sobre los receptores 5ht1a, 5ht1b y 5ht1d. |
| CN1478092A (zh) | 2000-10-26 | 2004-02-25 | ʷ | 苯并噁嗪酮衍生物及其制备和应用 |
| CA2364211A1 (en) | 2000-12-05 | 2002-06-05 | Phillip Branch Chappell | Combination treatment for depression, anxiety and psychosis |
| GB0106419D0 (en) * | 2001-03-15 | 2001-05-02 | Smithkline Beecham Plc | Novel compounds |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| GB0203804D0 (en) | 2002-02-18 | 2002-04-03 | Glaxo Group Ltd | Compounds |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| MXPA05004273A (es) | 2002-11-08 | 2005-10-18 | Warner Lambert Co | Derivados de fenilalquil y piridilalquil piperazina. |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| US6759435B1 (en) * | 2003-07-03 | 2004-07-06 | A.P. Group Inc. | Antidepressant drugs and methods |
| GB0316915D0 (en) * | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
| WO2005087745A1 (en) | 2004-03-10 | 2005-09-22 | Altana Pharma Ag | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
| PE20060653A1 (es) | 2004-08-31 | 2006-09-27 | Glaxo Group Ltd | Derivados triciclicos condensados como moduladores del receptor 5-ht1 |
-
2003
- 2003-07-18 GB GBGB0316915.8A patent/GB0316915D0/en not_active Ceased
-
2004
- 2004-07-15 MX MXPA06000716A patent/MXPA06000716A/es active IP Right Grant
- 2004-07-15 AU AU2004263268A patent/AU2004263268B2/en not_active Ceased
- 2004-07-15 ES ES04763307T patent/ES2302543T3/es not_active Expired - Lifetime
- 2004-07-15 DE DE602004012564T patent/DE602004012564T2/de not_active Expired - Lifetime
- 2004-07-15 EP EP04763307A patent/EP1646613B1/en not_active Expired - Lifetime
- 2004-07-15 EP EP07118193A patent/EP1876174B1/en not_active Expired - Lifetime
- 2004-07-15 CN CNB2004800270575A patent/CN100441571C/zh not_active Expired - Fee Related
- 2004-07-15 AT AT07118193T patent/ATE448205T1/de not_active IP Right Cessation
- 2004-07-15 US US10/565,066 patent/US7279481B2/en not_active Expired - Fee Related
- 2004-07-15 NZ NZ544586A patent/NZ544586A/en unknown
- 2004-07-15 PL PL04763307T patent/PL1646613T3/pl unknown
- 2004-07-15 EP EP09175186A patent/EP2145622A1/en not_active Withdrawn
- 2004-07-15 SI SI200430699T patent/SI1646613T1/sl unknown
- 2004-07-15 KR KR1020067001103A patent/KR20060041242A/ko not_active Application Discontinuation
- 2004-07-15 RU RU2006104993/04A patent/RU2402533C2/ru not_active IP Right Cessation
- 2004-07-15 WO PCT/EP2004/008000 patent/WO2005014552A1/en active IP Right Grant
- 2004-07-15 CA CA002532452A patent/CA2532452A1/en not_active Abandoned
- 2004-07-15 ES ES07118193T patent/ES2336148T3/es not_active Expired - Lifetime
- 2004-07-15 JP JP2006520756A patent/JP2006528146A/ja not_active Ceased
- 2004-07-15 AT AT04763307T patent/ATE389637T1/de active
- 2004-07-15 DE DE602004024141T patent/DE602004024141D1/de not_active Expired - Lifetime
- 2004-07-15 PT PT04763307T patent/PT1646613E/pt unknown
- 2004-07-15 BR BRPI0412695-5A patent/BRPI0412695A/pt not_active IP Right Cessation
- 2004-07-15 DK DK04763307T patent/DK1646613T3/da active
- 2004-07-16 AR ARP040102527A patent/AR046394A1/es not_active Application Discontinuation
- 2004-07-16 TW TW093121227A patent/TW200521115A/zh unknown
-
2006
- 2006-01-09 IL IL173036A patent/IL173036A0/en unknown
- 2006-01-18 MA MA28738A patent/MA27926A1/fr unknown
- 2006-02-15 IS IS8304A patent/IS2744B/is unknown
- 2006-02-17 NO NO20060774A patent/NO20060774L/no not_active Application Discontinuation
- 2006-09-01 HK HK06109772A patent/HK1089438A1/xx not_active IP Right Cessation
-
2007
- 2007-03-16 US US11/687,098 patent/US7459456B2/en not_active Expired - Fee Related
-
2008
- 2008-05-23 HR HR20080226T patent/HRP20080226T3/xx unknown
- 2008-05-29 CY CY20081100555T patent/CY1107974T1/el unknown
- 2008-07-02 US US12/166,547 patent/US7592346B2/en not_active Expired - Fee Related
-
2009
- 2009-08-13 US US12/540,452 patent/US7732600B2/en not_active Expired - Fee Related
-
2010
- 2010-04-23 US US12/766,053 patent/US20100204273A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1089438A1 (en) | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | |
| GB0322409D0 (en) | Quinazoline derivatives | |
| IL174534A0 (en) | Quinazoline derivatives | |
| PL372871A1 (en) | Quinolinone derivatives | |
| IL174284A0 (en) | Quinazoline derivatives | |
| HK1091479A1 (en) | Quinazoline derivatives | |
| HK1111417A1 (en) | Quinazoline derivatives | |
| GB0215823D0 (en) | Quinazoline derivatives | |
| GB0321648D0 (en) | Quinazoline derivatives | |
| IL164299A0 (en) | Radiolabelled quinoline and quinolinone derivatives and their use as metaboropic glutamate receptor ligands | |
| IL175421A0 (en) | Quinazoline derivatives | |
| IL174397A0 (en) | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | |
| IL172467A0 (en) | Quinolyl amide derivatives as ccr-5 antagonists | |
| IL174390A0 (en) | Quinazoline derivatives | |
| GB0330002D0 (en) | Quinazoline derivatives | |
| AU2002215043A1 (en) | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | |
| ZA200603039B (en) | Quinazoline derivatives | |
| IL163769A0 (en) | Quinoline derivatives | |
| PL374817A1 (en) | Quinazoline derivatives | |
| GB0321620D0 (en) | Quinazoline derivatives | |
| AU2002310838A1 (en) | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | |
| AU2002308138A1 (en) | 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | |
| GB0322534D0 (en) | Quinazoline derivatives | |
| GB0317664D0 (en) | Quinazoline derivatives | |
| GB0322410D0 (en) | Quinazoline derivatives |